Tetsuzo Wakatsuki

Tokyo, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 152 publications

Clinical implications of zolbetuximab-associated hypoalbuminemia in CLDN18.2-positive gastric or gastroesophageal junction cancer.

Clinical implications of zolbetuximab-associated hypoalbuminemia in CLDN18.2-positive gastric or gastroesophageal junction cancer.

Journal: ESMO gastrointestinal oncology

Published: August 12, 2026

BevRam-GC01 study protocol: a phase I trial of bevacizumab plus ramucirumab and paclitaxel in advanced gastric cancer.

BevRam-GC01 study protocol: a phase I trial of bevacizumab plus ramucirumab and paclitaxel in advanced gastric cancer.

Journal: ESMO gastrointestinal oncology

Published: April 17, 2026

Semiquantitative CLDN18 expression and clinical outcomes in patients with CLDN18-positive gastric cancer treated with zolbetuximab plus chemotherapy.

Semiquantitative CLDN18 expression and clinical outcomes in patients with CLDN18-positive gastric cancer treated with zolbetuximab plus chemotherapy.

Journal: ESMO gastrointestinal oncology

Published: April 17, 2026

Aspirin vs. Clopidogrel Monotherapy Beyond 1 Month After Percutaneous Coronary Intervention in Patients With Diabetes　- Prespecified Subgroup Analysis of the STOPDAPT-3 Trial.

Aspirin vs. Clopidogrel Monotherapy Beyond 1 Month After Percutaneous Coronary Intervention in Patients With Diabetes　- Prespecified Subgroup Analysis of the STOPDAPT-3 Trial.

Journal: Circulation journal : official journal of the Japanese Circulation Society

Published: March 18, 2026

The clinical utility of an mGPS and SII combined score in patients with advanced gastric cancer treated with nivolumab monotherapy.

The clinical utility of an mGPS and SII combined score in patients with advanced gastric cancer treated with nivolumab monotherapy.

Journal: ESMO gastrointestinal oncology

Published: February 06, 2026

Prognostic nutritional index as a prognostic marker in metastatic esophageal squamous-cell carcinoma treated with immune checkpoint inhibitor.

Prognostic nutritional index as a prognostic marker in metastatic esophageal squamous-cell carcinoma treated with immune checkpoint inhibitor.

Journal: ESMO gastrointestinal oncology

Published: February 06, 2026

Real-world clinical impact of first-line immune checkpoint inhibitor-based therapy in advanced esophageal squamous cell carcinoma.

Real-world clinical impact of first-line immune checkpoint inhibitor-based therapy in advanced esophageal squamous cell carcinoma.

Journal: ESMO gastrointestinal oncology

Published: February 06, 2026

Clinical efficacy of nivolumab-based therapy for HER2-negative diffuse-type advanced gastric or gastroesophageal junction adenocarcinoma with peritoneal dissemination.

Clinical efficacy of nivolumab-based therapy for HER2-negative diffuse-type advanced gastric or gastroesophageal junction adenocarcinoma with peritoneal dissemination.

Journal: ESMO gastrointestinal oncology

Published: February 06, 2026

Infective Endocarditis Complicated by Ventricular Septal Defect and Coarctation of the Aorta, Suspected on Auscultation and Phonocardiography.

Infective Endocarditis Complicated by Ventricular Septal Defect and Coarctation of the Aorta, Suspected on Auscultation and Phonocardiography.

Journal: Internal medicine (Tokyo, Japan)

Published: June 04, 2025

Successful or Uncomplicated Use of Drug-Coated Balloon Versus Drug-Eluting Stent Strategies for De Novo Culprit Lesions in Acute Coronary Syndromes: Insights from a Nationwide Registry in Japan.

Successful or Uncomplicated Use of Drug-Coated Balloon Versus Drug-Eluting Stent Strategies for De Novo Culprit Lesions in Acute Coronary Syndromes: Insights from a Nationwide Registry in Japan.

Journal: Journal of the American Heart Association

Published: May 29, 2025

Clinical and Echocardiographic Characteristics of Left Atrial Diverticulum.

Clinical and Echocardiographic Characteristics of Left Atrial Diverticulum.

Journal: Echocardiography (Mount Kisco, N.Y.)

Published: March 31, 2025

Managing zolbetuximab-induced nausea and vomiting: a proposal for a pragmatic approach in clinical practice.

Managing zolbetuximab-induced nausea and vomiting: a proposal for a pragmatic approach in clinical practice.

Journal: ESMO gastrointestinal oncology

Published: January 06, 2025

Showing 1-12 of 152

Last Updated: 09/26/2026